Kenvue Inc. (NYSE:KVUE - Get Free Report) declared a quarterly dividend on Thursday, April 25th, Zacks reports. Shareholders of record on Wednesday, May 8th will be given a dividend of 0.20 per share on Wednesday, May 22nd. This represents a $0.80 annualized dividend and a yield of 4.24%. The ex-dividend date is Tuesday, May 7th.
Kenvue has a payout ratio of 64.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Kenvue to earn $1.25 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 64.0%.
Kenvue Stock Performance
KVUE stock traded down $0.16 during midday trading on Friday, hitting $18.86. The company's stock had a trading volume of 15,451,237 shares, compared to its average volume of 16,691,828. The stock's 50-day moving average price is $19.84 and its 200 day moving average price is $20.14. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue has a 1 year low of $17.82 and a 1 year high of $27.80.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business had revenue of $3.67 billion for the quarter, compared to analysts' expectations of $3.78 billion. The company's quarterly revenue was down 2.7% on a year-over-year basis. As a group, research analysts predict that Kenvue will post 1.15 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on KVUE shares. JPMorgan Chase & Co. dropped their price target on Kenvue from $25.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein started coverage on Kenvue in a research report on Thursday, April 11th. They set an "underperform" rating and a $18.00 price target on the stock. The Goldman Sachs Group initiated coverage on Kenvue in a research report on Friday, March 1st. They set a "neutral" rating and a $20.00 price target on the stock. Royal Bank of Canada dropped their price objective on Kenvue from $25.00 to $24.00 and set an "outperform" rating on the stock in a report on Friday, February 9th. Finally, William Blair initiated coverage on Kenvue in a report on Wednesday, April 3rd. They set a "market perform" rating on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $24.85.
Check Out Our Latest Stock Report on Kenvue
Kenvue Company Profile
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
